Indivior Pharmaceuticals, Inc. (INDV) Institutional Ownership

Ownership Summary

Indivior Pharmaceuticals, Inc. (NASDAQ:INDV) showed up in the 13F filings of 197 institutional investors as of September 2025.

• These investors collectively held 286.2% of Indivior Pharmaceuticals's outstanding shares in September 2025, up from 88.3% in June 2025.
• They increased total shares held in INDV by 241.77% quarter over quarter, and investors in Indivior Pharmaceuticals increased 91.26% from a year ago.
• Of these 197 funds, 147 grew their exposure to Indivior Pharmaceuticals, 41 cut back, and 9 maintained positions.
• Altogether, these fund groups held 369.2Mn shares in INDV by September 2025, up by 261.18Mn shares quarter on quarter, and up 301.18Mn shares year over year.
• As of September 30, 2025, BlackRock, Inc. held the largest stake in Indivior Pharmaceuticals with 18.54Mn shares, accounting for 14.37% of total shares outstanding.
• The most significant purchases of INDV for the quarter ending September 2025 came from BlackRock, Inc. (18.54Mn), VANGUARD PORTFOLIO MANAGEMENT LLC (7.89Mn), VANGUARD CAPITAL MANAGEMENT LLC (5.59Mn), State Street Corp (4.9Mn), Two Seas Capital LP (4.75Mn).
• The largest sellers of Indivior Pharmaceuticals for the quarter ending September 2025 were Madison Avenue Partners, LP (1.97Mn), DRIEHAUS CAPITAL MANAGEMENT LLC (120.3K), Bare Financial Services, Inc (17).
• Per Business Quant data, the top 10 holders of Indivior Pharmaceuticals for the quarter ending September 2025 are BlackRock, Inc. (18.54Mn), VANGUARD PORTFOLIO MANAGEMENT LLC (7.89Mn), VANGUARD CAPITAL MANAGEMENT LLC (5.59Mn), State Street Corp (4.9Mn), Two Seas Capital LP (4.75Mn), MILLENNIUM MANAGEMENT LLC (4.6Mn), FULLER & THALER ASSET MANAGEMENT, INC. (4.53Mn), Madison Avenue Partners, LP (4.32Mn), CITADEL ADVISORS LLC (3.57Mn), Morgan Stanley (3.51Mn).